Collaborative Care for Opioid Use Disorder and Mental Health Conditions

KC
DM
TD
Overseen ByTiffany DeMenna, BA
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Pennsylvania
Must be taking: Opioid use disorder medications
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The trial aims to improve care for individuals with both opioid use disorder (OUD) and mental health issues such as depression, anxiety, or PTSD. It will test various care methods in primary care settings, including standard care and enhanced collaborative care models, some of which include a certified recovery specialist to support recovery. The trial suits those diagnosed with OUD within the past year and experiencing challenges with depression, anxiety, or PTSD. Participants should be open to receiving medication for OUD at their primary care clinic.

As an unphased trial, this study offers a unique opportunity to contribute to innovative care models that could enhance treatment for OUD and mental health issues.

Will I have to stop taking my current medications?

The trial protocol does not specify whether you need to stop taking your current medications. However, you must agree to receive medication for opioid use disorder at the primary care site.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that collaborative care models can improve access to and quality of treatment for individuals with opioid use disorder (OUD) and mental health issues such as depression, anxiety, and PTSD. While studies do not highlight specific safety details for these care models, their common use in medical settings suggests they are generally considered safe.

Regarding the addition of Certified Recovery Specialists (CRS) to the collaborative care model, specific safety data is unavailable. However, the CRS role supports patients in their treatment and offers peer support, which is viewed as helpful and positive in recovery settings, indicating it is well-accepted.

The absence of detailed safety data may be because this trial focuses on enhancing existing care models rather than testing a new drug or treatment. This typically implies that the treatment methods are considered relatively safe, as they are already in use.12345

Why are researchers excited about this trial?

Researchers are excited about these treatments because they offer a more integrated approach to tackling opioid use disorder (OUD) combined with mental health conditions. Unlike traditional care, the Collaborative Care model incorporates a dedicated care manager and an addictions psychiatrist to guide treatment, ensuring holistic attention to both substance use and mental health. The addition of Certified Recovery Specialists (CC+) is particularly promising as it introduces peer support, potentially boosting patient engagement and retention by providing personalized navigation and support from someone who has faced similar challenges. This comprehensive, team-based approach could lead to more effective management of both OUD and associated mental health issues, offering hope for better patient outcomes.

What evidence suggests that this trial's treatments could be effective for opioid use disorder and mental health conditions?

Research shows that team-based care for treating opioid addiction and mental health issues holds promise. In this trial, participants may receive one of several treatment approaches. Studies have found that the Collaborative Care model, one of the study arms, greatly reduces opioid use and aids with mental health problems like depression and anxiety, which often accompany opioid addiction. Another arm, Collaborative Care Plus Certified Recovery Specialist (CC+), includes a Certified Recovery Specialist (CRS) who provides extra support through peer guidance and helps patients stay committed to their treatment. This approach aims to improve overall health and recovery by addressing both addiction and mental health needs together.12346

Who Is on the Research Team?

DM

David Mandell, PhD

Principal Investigator

University of Pennsylvania

Are You a Good Fit for This Trial?

This trial is for adults over 18 with opioid use disorder and a mental health condition like depression, anxiety, or PTSD. Participants must have been diagnosed or treated for OUD within the last year, speak English, consent to treatment at the primary care site using buprenorphine-naloxone or naltrexone injections, and be willing to give informed consent. Those acutely suicidal, manic, psychotic or without a phone are excluded.

Inclusion Criteria

able to communicate in a language that is understood by most people.
I have been diagnosed with depression, anxiety, or PTSD.
Willing to give informed consent
See 7 more

Exclusion Criteria

Lack of a phone.
Acutely suicidal and needs immediate hospitalization, manic or psychotic (patients will not be randomized and PI or study physician covering for PI will be notified immediately)

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive collaborative care for OUD and mental health conditions, including pharmacotherapy and care management

6 months
Monthly visits (in-person and virtual)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Open-label extension (optional)

Participants may opt into continuation of treatment long-term

Long-term

What Are the Treatments Tested in This Trial?

Interventions

  • Augmented Usual Care
  • Collaborative Care for Opioid Use Disorders and Mental Health Conditions
  • Collaborative Care for Opioid Use Disorders and Mental Health Conditions Plus Certified Recovery Specialists
Trial Overview The study tests a collaborative care model in primary care for patients with both opioid use disorder (OUD) and certain mental health conditions. It compares standard care against this model plus support from certified recovery specialists. The goal is to refine care approaches for OUD alongside depression, anxiety disorders or PTSD.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Active Control
Group I: Collaborative Care + Certified Recovery Specialist (CC+)Experimental Treatment1 Intervention
Group II: Collaborative Care (CC)Experimental Treatment1 Intervention
Group III: Augmented Usual Care (AUC)Active Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Pennsylvania

Lead Sponsor

Trials
2,118
Recruited
45,270,000+

Weill Medical College of Cornell University

Collaborator

Trials
1,103
Recruited
1,157,000+

Published Research Related to This Trial

A collaborative care model for treating pregnant patients with opioid use disorder using buprenorphine was shown to be feasible, with 93.8% of pregnancies continuing treatment until delivery.
Most infants (80%) required NICU admission for monitoring or treatment of neonatal abstinence syndrome, highlighting the need for ongoing research to enhance outcomes for mothers and their babies.
Feasibility of collaborative care treatment of opioid use disorders with buprenorphine during pregnancy.Mittal, L., Suzuki, J.[2018]
A program in Maine successfully created collaboratives of mental health and substance abuse providers, improving coordinated treatment for individuals with both psychiatric and substance use disorders.
Surveys conducted one and two years after the program's establishment showed significant increases in interagency referrals, joint client assessments, and collaborative training efforts among providers.
Interagency collaboration in services for people with co-occurring mental illness and substance use disorder.Ridgely, MS., Lambert, D., Goodman, A., et al.[2006]
The PROUD trial is testing a collaborative care model in primary care settings to improve treatment access for opioid use disorder (OUD), involving over 170,000 patients across six health care systems.
The trial aims to measure the effectiveness of this model by comparing the number of days patients receive medication for OUD and the reduction in acute health care utilization, providing valuable insights for future OUD management strategies.
PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment.Campbell, CI., Saxon, AJ., Boudreau, DM., et al.[2022]

Citations

Collaborative Care in the Treatment of Opioid Use Disorder ...Primary outcomes are six-month rates of opioid use and six-month rates of remission of co-occurring psychiatric disorders. Discussion: The Whole Health Study ...
Collaborative Care for Opioid Use Disorder in Primary CareObjective To compare the effectiveness of CCM for OUD and co-occurring mental health symptoms (intervention) with CCM for mental health symptoms ...
The Whole Health Study: Collaborative Care for OUD and ...This study will refine and test a collaborative care model for patients with opioid use disorder (OUD) and depression, anxiety or post-traumatic stress ...
Collaborative care in the treatment of opioid use disorder ...Primary outcomes are six-month rates of opioid use and six-month rates of remission of co-occurring psychiatric disorders. Discussion. The Whole Health Study ...
Managing Opioid Use Disorder Through Collaborative CareA primary care–based collaborative care model significantly cut opioid use, though mental health outcomes remained unchanged.
Collaborative Care for Opioid Use Disorder and Mental ...The research does not provide specific safety data for collaborative care in treating opioid use disorder and mental health conditions, but it is generally ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security